<DOC>
	<DOCNO>NCT02563951</DOCNO>
	<brief_summary>The purpose study examine pharmacokinetics ( PK ) , safety tolerability 3 intranasal ( IN ) dose ( 0.5 , 1.0 2.0 mg ) Granisetron Hydrochloride Nasal Sprays ( GNS ) compare Granisetron IV Injection Granisetron Tablet healthy Volunteers .</brief_summary>
	<brief_title>Study Granisetron Hydrochloride Nasal Spray ( GNS ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Granisetron</mesh_term>
	<criteria>1 . Healthy male female age 2064 year 2 . Body Mass Index ( BMI ) 18.5 ( inclusive ) 24 kg/m2 ; total body weight &gt; 45 kg 3 . Accessible vein blood sample 4 . No significant abnormality electrocardiogram ( ECG ) record per site ' local practice 5 . No significant abnormality general physical examination per site ' local practice 6 . No significantly abnormal finding laboratory assessment include hematology , biochemistry urinalysis per site 's local practice 7 . A signed date write informed consent must obtain subject prior study participation 8 . Capable understand willing comply study procedures 9 . A negative serum pregnancy test first dose study drug must available woman childbearing potential 1 . Females pregnant , breastfeed positive pregnancy test 2 . History hypersensitivity granisetron analog 3 . Subjects nasal ulcer , septal perforation , nasal condition may interfere nasal administration determine investigator ineligible 4 . Subjects QT interval great 500 m acute ischemic change cardiac abnormality predispose arrhythmia screen electrocardiogram ( ECG ) history 5 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , significant disease clinical finding screen determine investigator ineligible 6 . Subjects history drug and/or alcohol abuse within 12 month prior dose 7 . Inability read and/or sign consent form 8 . Treatment investigational drug 4 week prior initial dose study 9 . Subjects donate lose 250 ml blood within 2 month prior initial dose study 10 . Male female subject reproductive potential willing use effective method contraception . Use hormonal contraceptive allow study period 11 . Clinical significant rhinitis rhinorrhea screen determine investigator ineligible 12 . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior dose study medication 13 . For subject smoke use tobacco product currently use nicotine product ( patch , gum , etc . ) , 2 week abstinence require 14 . Conditions upon screen might contraindicate require caution use administration granisetron</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiation therapy</keyword>
</DOC>